RESUMEN
Piper claussenianum inflorescences crude methanol extract was tested for hypoglycemic effect in streptozotocin-induced diabetic rats. The blood glucose levels of rats treated with methanol extract were reduced from 318.4±28.1 mg/dl before treatment to 174.2±38.3 mg/dl after 12 days of treatment (P<0.05). Phytochemical studies were carried out on inflorescences methanol crude extract in order to investigate the possible metabolites responsible for the pharmacological properties of the extract. After chromatographic procedures, three flavonoids were isolated and characterized. The major compound 2',6'-dihydroxy-4'-methoxychalcone was also tested. Rats that received the chalcone content also displayed a reduction in blood glucose levels from 277.4±7.7 mg/dl before treatment to 158.8±9.2 mg/dl after 12 days of treatment (P<0.05). The results suggest this chalcone is one of the metabolite responsible for the blood glucose levels reduction in rats with streptozotocin-induced diabetes. The inflorescence crude extract of P. claussenianum was found to be composed mainly by flavonoids and may be a potential natural source of compounds with hypoglycemic properties.
RESUMEN
The N-acylhydrazone (NAH) analogues N-methyl 2-thienylidene 3,4-benzoylhydrazine (LASSBio-785) and N-benzyl 2-thienylidene 3,4-benzoylhydrazine (LASSBio-786) were prepared from 2-thienylidene 3,4-methylenedioxybenzoylhydrazine (LASSBio-294). The ability of LASSBio-785 and LASSBio-786 to decrease central nervous system activity was investigated in male Swiss mice. LASSBio-785 or LASSBio-786 (30â mg/kg, ip) reduced locomotor activity from 209 ± 26 (control) to 140 ± 18 (P < 0.05) or 146 ± 15 crossings/min (P < 0.05), respectively. LASSBio-785 (15 or 30â mg/kg, iv) also reduced locomotor activity from 200 ± 15 to 116 ± 29 (P < 0.05) or 60 ± 16 crossings/min (P < 0.01), respectively. Likewise, LASSBio-786 (15 or 30â mg/kg, iv) reduced locomotor activity from 200 ± 15 to 127 ± 10 (P < 0.01) or 96 ± 14 crossings/min (P < 0.01), respectively. Pretreatment with flumazenil (20â mg/kg, ip) prevented the locomotor impairment induced by NAH analogues (15â mg/kg, iv), providing evidence that the benzodiazepine (BDZ) receptor is involved. This finding was supported by the structural similarity of NAH analogues to midazolam. However, LASSBio-785 showed weak binding to the BDZ receptor. LASSBio-785 or LASSBio-786 (30â mg/kg, ip, n = 10) increased pentobarbital-induced sleeping time from 42 ± 5 (DMSO) to 66 ± 6 (P < 0.05) or 75 ± 4â min (P < 0.05), respectively. The dose required to achieve 50% hypnosis (HD50) following iv injection of LASSBio-785 or LASSBio-786 was 15.8 or 9.5â mg/kg, respectively. These data suggest that both NAH analogues might be useful for the development of new neuroactive drugs for the treatment of insomnia or for use in conjunction with general anesthesia.
Asunto(s)
Hidrazinas/farmacología , Hidrazonas/farmacología , Hipnóticos y Sedantes/farmacología , Actividad Motora/efectos de los fármacos , Receptores de GABA/efectos de los fármacos , Tiofenos/farmacología , Animales , Hidrazinas/química , Hidrazonas/química , Masculino , Ratones , Receptores de GABA/fisiología , Tiofenos/químicaRESUMEN
The N-acylhydrazone (NAH) analogues N-methyl 2-thienylidene 3,4-benzoylhydrazine (LASSBio-785) and N-benzyl 2-thienylidene 3,4-benzoylhydrazine (LASSBio-786) were prepared from 2-thienylidene 3,4-methylenedioxybenzoylhydrazine (LASSBio-294). The ability of LASSBio-785 and LASSBio-786 to decrease central nervous system activity was investigated in male Swiss mice. LASSBio-785 or LASSBio-786 (30 mg/kg, ip) reduced locomotor activity from 209 ± 26 (control) to 140 ± 18 (P < 0.05) or 146 ± 15 crossings/min (P < 0.05), respectively. LASSBio-785 (15 or 30 mg/kg, iv) also reduced locomotor activity from 200 ± 15 to 116 ± 29 (P < 0.05) or 60 ± 16 crossings/min (P < 0.01), respectively. Likewise, LASSBio-786 (15 or 30 mg/kg, iv) reduced locomotor activity from 200 ± 15 to 127 ± 10 (P < 0.01) or 96 ± 14 crossings/min (P < 0.01), respectively. Pretreatment with flumazenil (20 mg/kg, ip) prevented the locomotor impairment induced by NAH analogues (15 mg/kg, iv), providing evidence that the benzodiazepine (BDZ) receptor is involved. This finding was supported by the structural similarity of NAH analogues to midazolam. However, LASSBio-785 showed weak binding to the BDZ receptor. LASSBio-785 or LASSBio-786 (30 mg/kg, ip, n = 10) increased pentobarbital-induced sleeping time from 42 ± 5 (DMSO) to 66 ± 6 (P < 0.05) or 75 ± 4 min (P < 0.05), respectively. The dose required to achieve 50% hypnosis (HD50) following iv injection of LASSBio-785 or LASSBio-786 was 15.8 or 9.5 mg/kg, respectively. These data suggest that both NAH analogues might be useful for the development of new neuroactive drugs for the treatment of insomnia or for use in conjunction with general anesthesia.
Asunto(s)
Animales , Masculino , Ratones , Hidrazinas/farmacología , Hidrazonas/farmacología , Hipnóticos y Sedantes/farmacología , Actividad Motora/efectos de los fármacos , Receptores de GABA/efectos de los fármacos , Tiofenos/farmacología , Hidrazinas/química , Hidrazonas/química , Receptores de GABA/fisiología , Tiofenos/químicaRESUMEN
BACKGROUND: The efficacy of intravenous (IV) administration of azumolene (Az), an analogue 30-fold more soluble than dantrolene, on pigs susceptible to malignant hyperthermia (MH) is incompletely understood. OBJECTIVE: To evaluate efficacy of Az on MH crisis in pigs. ANIMALS: Eight normal (MHN) and 7 susceptible to MH (MHS) pigs (Landrace × Large White × Pietran). METHODS: Prospective, laboratory trial. Hypermetabolic crisis was observed in MHS pigs, but not in MHN pigs, after a combined administration of inhaled halothane (1.5%) and IV injection of succinylcholine (SCh; 2.5 mg/kg). Susceptibility was confirmed using a caffeine and halothane contracture test. Az was administered 15 minutes after administration of SCh. RESULTS: Respiratory acidosis (pH 7.16 ± 0.02; Pco(2) , 46.2 ± 9.1 mmHg, HCO(3) , 22.5 ± 2.3 mmol/L), fever (38.2 ± 1.1°C), cardiac arrhythmias, and muscle contracture were observed in MHS pigs. MHS pigs (n = 5) treated with Az (2 mg/kg IV) survived the crisis with attenuation of signs (pH 7.30 ± 0.10; Pco(2) , 36.3 ± 4.5 mmHg; HCO(3) , 22.9 ± 2.3 mmol/L) and recovery of normal muscle tone and cardiac rhythm. CONCLUSIONS AND CLINICAL IMPORTANCE: Az represents a possible substitute for dantrolene to reverse MH crisis in susceptible pigs.
Asunto(s)
Analgésicos no Narcóticos/administración & dosificación , Analgésicos no Narcóticos/uso terapéutico , Imidazoles/administración & dosificación , Imidazoles/uso terapéutico , Hipertermia Maligna/veterinaria , Oxazoles/administración & dosificación , Oxazoles/uso terapéutico , Enfermedades de los Porcinos/tratamiento farmacológico , Anestésicos por Inhalación/efectos adversos , Animales , Femenino , Genotipo , Halotano/efectos adversos , Masculino , Hipertermia Maligna/tratamiento farmacológico , Hipertermia Maligna/etiología , Hipertermia Maligna/genética , Porcinos , Enfermedades de los Porcinos/genéticaRESUMEN
Malignant hyperthermia (MH) is a pharmacogenetic disease triggered by volatile anesthetics and succinylcholine. Deaths due to MH have been reported in Brazil. The first Malignant Hyperthermia Diagnostic and Research Center in Latin America was inaugurated in 1993 at the Federal University of Rio de Janeiro, Brazil. The center followed the diagnostic protocols of the North America MH Group, in which the contractures of biopsies from the vastus lateralis muscle are analyzed after exposure to caffeine and halothane (CHCT). CHCT was performed in individuals who survived, their relatives and those with signs/symptoms somewhat related to MH susceptibility (MHS). Here, we report data from 194 patients collected over 16 years. The Southeast (N = 110) and South (N = 71) represented the majority of patients. Median age was 25 (4-70) years, with similar numbers of males (104) and females (90). MHS was found in 90 patients and 104 patients were normal. Abnormal responses to both caffeine and halothane were observed in 59 patients and to caffeine or halothane in 20 and 11 patients, respectively. The contracture of biopsies from MHS exposed to caffeine and halothane was 1.027 ± 0.075 g (N = 285) and 4.021 ± 0.255 g (N = 226), respectively. MHS was found in patients with either low or high blood creatine kinase and also, with a low score on the clinical grading scale. Thus, these parameters cannot be used with certainty to predict MHS. We conclude that the CHCT protocol described by the North America MH Group contributed to identification of MHS in suspected individuals at an MH center in Brazil with 100 percent sensitivity and 65.7 percent specificity.
Asunto(s)
Adolescente , Adulto , Anciano , Niño , Preescolar , Femenino , Humanos , Masculino , Persona de Mediana Edad , Adulto Joven , Anestésicos por Inhalación , Cafeína , Contractura/inducido químicamente , Halotano , Hipertermia Maligna/diagnóstico , Biopsia , Contractura/fisiopatología , Hipertermia Maligna/fisiopatología , Sensibilidad y Especificidad , Índice de Severidad de la Enfermedad , Adulto JovenRESUMEN
Malignant hyperthermia (MH) is a pharmacogenetic disease triggered by volatile anesthetics and succinylcholine. Deaths due to MH have been reported in Brazil. The first Malignant Hyperthermia Diagnostic and Research Center in Latin America was inaugurated in 1993 at the Federal University of Rio de Janeiro, Brazil. The center followed the diagnostic protocols of the North America MH Group, in which the contractures of biopsies from the vastus lateralis muscle are analyzed after exposure to caffeine and halothane (CHCT). CHCT was performed in individuals who survived, their relatives and those with signs/symptoms somewhat related to MH susceptibility (MHS). Here, we report data from 194 patients collected over 16 years. The Southeast (N = 110) and South (N = 71) represented the majority of patients. Median age was 25 (4-70) years, with similar numbers of males (104) and females (90). MHS was found in 90 patients and 104 patients were normal. Abnormal responses to both caffeine and halothane were observed in 59 patients and to caffeine or halothane in 20 and 11 patients, respectively. The contracture of biopsies from MHS exposed to caffeine and halothane was 1.027 +/- 0.075 g (N = 285) and 4.021 +/- 0.255 g (N = 226), respectively. MHS was found in patients with either low or high blood creatine kinase and also, with a low score on the clinical grading scale. Thus, these parameters cannot be used with certainty to predict MHS. We conclude that the CHCT protocol described by the North America MH Group contributed to identification of MHS in suspected individuals at an MH center in Brazil with 100% sensitivity and 65.7% specificity.
Asunto(s)
Anestésicos por Inhalación , Cafeína , Contractura/inducido químicamente , Halotano , Hipertermia Maligna/diagnóstico , Adolescente , Adulto , Anciano , Biopsia , Niño , Preescolar , Contractura/fisiopatología , Femenino , Humanos , Masculino , Hipertermia Maligna/fisiopatología , Persona de Mediana Edad , Sensibilidad y Especificidad , Índice de Severidad de la Enfermedad , Adulto JovenRESUMEN
Malignant hyperthermia (MH) is a pharmacogenetic disease triggered in susceptible individuals by the administration of volatile halogenated anesthetics and/or succinylcholine, leading to the development of a hypermetabolic crisis, which is caused by abnormal release of Ca2+ from the sarcoplasmic reticulum, through the Ca2+ release channel ryanodine receptor 1 (RyR1). Mutations in the RYR1 gene are associated with MH in the majority of susceptible families. Genetic screening of a 5-generation Brazilian family with a history of MH-related deaths and a previous MH diagnosis by the caffeine halothane contracture test (CHCT) in some individuals was performed using restriction and sequencing analysis. A novel missense mutation, Gly4935Ser, was found in an important functional and conserved locus of this gene, the transmembrane region of RyR1. In this family, 2 MH-susceptible individuals previously diagnosed with CHCT carry this novel mutation and another 24 not previously diagnosed members also carry it. However, this same mutation was not found in another MH-susceptible individual whose CHCT was positive to the test with caffeine but not to the test with halothane. None of the 5 MH normal individuals of the family, previously diagnosed by CHCT, carry this mutation, nor do 100 controls from control Brazilian and USA populations. The Gly4932Ser variant is a candidate mutation for MH, based on its co-segregation with disease phenotype, absence among controls and its location within the protein.
Asunto(s)
Femenino , Humanos , Masculino , Hipertermia Maligna/genética , Mutación Missense/genética , Linaje , Canal Liberador de Calcio Receptor de Rianodina/genética , Brasil , Contractura , Cafeína , Familia , Pruebas Genéticas , Halotano , Hipertermia Maligna/diagnósticoRESUMEN
Malignant hyperthermia (MH) is a pharmacogenetic disease triggered in susceptible individuals by the administration of volatile halogenated anesthetics and/or succinylcholine, leading to the development of a hypermetabolic crisis, which is caused by abnormal release of Ca2+ from the sarcoplasmic reticulum, through the Ca2+ release channel ryanodine receptor 1 (RyR1). Mutations in the RYR1 gene are associated with MH in the majority of susceptible families. Genetic screening of a 5-generation Brazilian family with a history of MH-related deaths and a previous MH diagnosis by the caffeine halothane contracture test (CHCT) in some individuals was performed using restriction and sequencing analysis. A novel missense mutation, Gly4935Ser, was found in an important functional and conserved locus of this gene, the transmembrane region of RyR1. In this family, 2 MH-susceptible individuals previously diagnosed with CHCT carry this novel mutation and another 24 not previously diagnosed members also carry it. However, this same mutation was not found in another MH-susceptible individual whose CHCT was positive to the test with caffeine but not to the test with halothane. None of the 5 MH normal individuals of the family, previously diagnosed by CHCT, carry this mutation, nor do 100 controls from control Brazilian and USA populations. The Gly4932Ser variant is a candidate mutation for MH, based on its co-segregation with disease phenotype, absence among controls and its location within the protein.
Asunto(s)
Hipertermia Maligna/genética , Mutación Missense/genética , Linaje , Canal Liberador de Calcio Receptor de Rianodina/genética , Brasil , Cafeína , Contractura , Familia , Femenino , Pruebas Genéticas , Halotano , Humanos , Masculino , Hipertermia Maligna/diagnósticoRESUMEN
BACKGROUND: Racemic [RS(+/-)] bupivacaine can be associated with severe cardiotoxicity. The S(-) isomer is known to be less neuro- and cardiotoxic, but demonstrates a lower potency to block motor activity than RS(+/-) bupivacaine. Thus, the potency and toxicity of a non-racemic bupivacaine mixture were studied. METHODS: Gastrocnemic muscle twitches induced by electrical stimulation of sciatic nerves in rats were used to compare the impact by bupivacaine solutions on motor activity. Field stimulation at 1 Hz eliciting ventricular muscle twitches was used to investigate the effects on cardiac contractility. The lethal dose of each local anesthetic agent was determined following drug infusions during general anesthesia in mechanically ventilated rats. RESULTS: Non-racemic (75S:25R) bupivacaine was more potent (P<0.05) than S(-) or R(+) enantiomers to block motor nerve activity. The concentrations of RS(+/-), 75S:25R, R(+) and S(-) bupivacaine to inhibit nerve conduction by 50% were 0.84 (0.37- 2.20), 0.84 (0.47-2.48), 2.68 (0.98-3.42) and 2.11 mM (1.5-4.03), respectively. Pronounced reductions in ventricular muscle twitches were observed with RS(+/-) and R(+) bupivacaine at low concentrations (0.5-4 microM). Lethal doses for 75S:25R (39.9 mg kg(-1)), and S(-) (34.7 mg kg(-1)) were higher (P<0.05) than for R(+) (16.2 mg kg(-1)) and RS(+/-) bupivacaine (18.4 mg kg(-1)), respectively. DISCUSSION: The potency of S(-) bupivacaine to block the motor activity in the sciatic nerve was enhanced when 25% of the S(-) isomer was replaced by the antipode R(+) bupivacaine. This effect was not associated with increased toxicity.
Asunto(s)
Anestésicos Locales/farmacología , Bupivacaína/farmacología , Neuronas Motoras/efectos de los fármacos , Bloqueo Nervioso , Anestésicos Locales/química , Anestésicos Locales/toxicidad , Animales , Bupivacaína/química , Bupivacaína/toxicidad , Corazón/efectos de los fármacos , Técnicas In Vitro , Contracción Isométrica/efectos de los fármacos , Dosificación Letal Mediana , Músculo Liso/efectos de los fármacos , Músculo Liso Vascular/efectos de los fármacos , Músculo Liso Vascular/inervación , Ratas , Ratas Wistar , Nervio Ciático/efectos de los fármacos , Nervio Ciático/fisiología , EstereoisomerismoRESUMEN
Malignant hyperthermia (MH) is an autosomal dominant disorder that predisposes susceptible individuals to a potentially life-threatening crisis when exposed to commonly used anesthetics. Mutations in the skeletal muscle calcium release channel, ryanodine receptor (RYR1) are associated with MH in over 50% of affected families. Linkage analysis of the RYR1 gene region at 19q13 was performed in a large Brazilian family and a distinct disease co-segregating haplotype was revealed in the majority of members with diagnosis of MH. Subsequent sequencing of RYR1 mutational hot spots revealed a nucleotide substitution of C to T at position 7062, causing a novel amino acid change from Arg2355 to Cys associated with MH in the family. Haplotype analysis of the RYR1 gene area at 19q13 in the family with multiple MH members is an important tool in identification of genetic cause underlying this disease.
Asunto(s)
Hipertermia Maligna/genética , Músculo Esquelético/metabolismo , Canal Liberador de Calcio Receptor de Rianodina/genética , Sustitución de Aminoácidos , Brasil , Femenino , Haplotipos , Humanos , Masculino , Hipertermia Maligna/metabolismo , Mutación , Linaje , Canal Liberador de Calcio Receptor de Rianodina/metabolismoRESUMEN
1. A new compound designated as LASSBio 294 (L-294), 3,4-methylenedioxybenzoyl-2-thienylhydrazone, was synthesized as an alternative therapeutic for cardiac dysfunction. 2. L-294 increased in a dose-dependent manner the spontaneous contractions of isolated hearts from Wistar rats with maximal effect (128.0+/-0.7% of control) observed at 25 microM. 3. The positive inotropic effect of L-294 was also observed in electrically stimulated cardiac tissues from Wistar rats. The maximal increment of twitches, at 200 microM, was 163.1+/-18.4% for atrial, 153.5+/-28.5% for papillary and 201.5+/-18.5% for ventricular muscles. 4. In saponin skinned ventricular cells: (a) L-294 present in the period of sarcoplasmic reticulum (SR) loading with Ca(2+) shifted the dose and caffeine-induced contracture curve; (b) L-294 (100 microM) increased 40% the Ca(2+) uptake into SR; (c) L-294 did not significantly alter the sensitivity of contractile proteins to Ca(2+) in SR-disrupted skinned ventricular cells. 5. Retrograde perfusion of the isolated heart from Wistar rats with L-294 (100 microM) did not cause any significant change in rhythm, heart rate (control, 220+/-14.7 b.p.m.; 246+/-24.6 b.p.m. for L-294), PR interval (control, 66.0+/-2.4 ms; 64.0+/-2.3 ms for L-294) or QRS duration (control, 28.8+/-3.4 ms; 32.0+/-2.0 ms for L-294). 6. These results suggest a novel mechanism for a positive cardioinotropic effect through an interaction with the Ca(2+) uptake/release process of the SR. The effect of L-294 could be explained by a pronounced increased accumulation of Ca(2+) into the SR.
Asunto(s)
Cardiotónicos/farmacología , Hidrazonas/farmacología , Contracción Miocárdica/efectos de los fármacos , Músculos Papilares/efectos de los fármacos , Saponinas/farmacología , Tiofenos/farmacología , Animales , Relación Dosis-Respuesta a Droga , Ventrículos Cardíacos/efectos de los fármacos , Hidrazonas/química , Técnicas In Vitro , Contracción Isométrica/efectos de los fármacos , Contracción Isométrica/fisiología , Masculino , Contracción Miocárdica/fisiología , Músculos Papilares/fisiología , Ratas , Tiofenos/química , Función VentricularRESUMEN
Cardiac toxicity can occur after accidental intravascular injection of bupivacaine. Racemic bupivacaine can inhibit both cardiac Na(+) and Ca(2+) channels, but the contribution of these actions to cardiac depression is not totally understood. We tested whether the effect of R(+) bupivacaine on cardiac electrical activity in isolated hearts and on L-type Ca(2+) channels (I(Ca-L)) in isolated cardiac myocytes could be responsible for its increased cardiotoxicity compared with S(-) bupivacaine. Cardiac electrical activity of spontaneously beating isolated hearts was recorded before and after exposure to increasing concentrations of R(+) and S(-) bupivacaine. An increase of the PR interval (80%) and the QRS duration (370%) by 10microM R(+) bupivacaine (80% and 370%) was significantly higher than for S(-) bupivacaine (25% and 200%, respectively). R(+) but not S(-) bupivacaine produced severe arrhythmias at concentrations larger than 2.5microM. The intensity of I(Ca-L) inhibition did not differ between bupivacaine isomers. At 0 mV, I(Ca-L) was irreversibly reduced by 40.2% +/- 8.8% and 51.4% +/- 3.8% in the presence of 10microM R(+) and S(-) bupivacaine, respectively. The arrhythmogenic effect of R(+) bupivacaine could not be explained by stereoselectivity on the I(Ca-L) inhibition. Thus, other mechanisms could contribute to the cardiac electrical and contractile dysfunction induced by R(+) bupivacaine.
Asunto(s)
Anestésicos Locales/toxicidad , Bupivacaína/toxicidad , Bloqueadores de los Canales de Calcio/farmacología , Canales de Calcio Tipo L/efectos de los fármacos , Corazón/efectos de los fármacos , Animales , Electrocardiografía/efectos de los fármacos , Masculino , Ratas , Ratas Wistar , Canales de Sodio/efectos de los fármacos , EstereoisomerismoRESUMEN
Elective diagnosis of malignant hyperthermia depends on halothane and caffeine contracture testing of biopsied skeletal muscle. Ryanodine-induced contractures may provide greater sensitivity and specificity for malignant hyperthermia (MH) diagnosis. This study investigated the effects of ryanodine concentration and stimulus frequency to distinguish between MH susceptible (MHS) and MH non-susceptible (MHN) dogs. Increasing ryanodine concentrations (1, 2.5 and 5 microM) increased peak isometric contracture tension, but similar responses in MHS and MHN muscle precluded use for diagnosis. Time to tension onset and to peak tension decreased with increasing ryanodine concentration, and these times were shorter in MH skeletal muscle. Increasing stimulus frequency (0.1, 0.5 and 1 Hz) decreased the time to tension onset and to peak tension, but the effect was greater in MHN muscle which decreased the difference between MHN and MHS muscle responses. When ryanodine contracture tension onset time was selected to detect MHS muscle, combinations of either 0.1 Hz and 1 microM ryanodine or 0.5 Hz and 1 microM ryanodine reduced the probabilty of a false diagnosis to less than 1%. Similar studies performed on human muscle might identify optimal stimulus frequency and ryanodine concentration for detecting MH in patients.
Asunto(s)
Hipertermia Maligna/fisiopatología , Contracción Muscular/efectos de los fármacos , Músculo Esquelético/efectos de los fármacos , Rianodina/farmacología , Animales , Perros , Relación Dosis-Respuesta a Droga , Estimulación Eléctrica , Técnicas In Vitro , Músculo Esquelético/fisiologíaRESUMEN
Myocardial contractile failure is a common cause of morbidity and mortality in patients with ischemic heart disease and systemic inflammatory states such as sepsis. Accumulating evidence indicates that contractile failure is associated with dysregulation of myoplasmic calcium levels. In a search for biochemical causes for contractile dysfunction, we found that the dipeptide carnosine improves cardiac contractility and tested the possibility that carnosine plays a role in the regulation of intracellular calcium. Carnosine increased contractility in a dose-dependent manner (1-10 mM) in isolated perfused rat hearts. and it also increased free intracellular calcium levels in isolated myocytes. Carnosine increased myocyte tension via calcium release from the ryanodine receptor calcium release channel in skinned myocardial fibers and increased open-state probability and dwell time of the isolated ryanodine receptor calcium release channel in lipid bilayers. In addition. we report that carnosine sensitizes the contractile proteins so calcium. These results suggest a novel role for carnosine as a modulator of intracellular calcium and contractility in cardiac tissue.
Asunto(s)
Calcio/metabolismo , Carnosina/farmacología , Corazón/efectos de los fármacos , Membranas Intracelulares/metabolismo , Contracción Miocárdica/efectos de los fármacos , Miocardio/metabolismo , Animales , Canales de Calcio/efectos de los fármacos , Canales de Calcio/metabolismo , AMP Cíclico/biosíntesis , Ventrículos Cardíacos , Técnicas Histológicas , Técnicas In Vitro , Masculino , Proteínas Musculares/efectos de los fármacos , Proteínas Musculares/metabolismo , Miocardio/citología , Ratas , Ratas Sprague-Dawley , Canal Liberador de Calcio Receptor de RianodinaRESUMEN
BACKGROUND: Dantrolene sodium (DS) is a direct-acting skeletal muscle relaxant whose only known action is to block calcium release from intracellular storage sites. The exact site of action for DS is unknown, but its efficacy in treating and preventing anesthetic-induced malignant hyperthermia (MH) is well established. METHODS: Single ryanodine (Ry1) receptor calcium release channels were incorporated into a planar lipid bilayer for electrophysiologic recording and for subsequent analysis of the channel's gating and conductance properties. The cellular effects of low DS concentrations were investigated by isometric contracture tension responses in biopsied MH human and dog muscle fascicles and in normal, single fibers from human vastus lateralis muscle. RESULTS: Two concentration-dependent DS effects on the isolated Ry1 receptor were discovered, suggesting at least two different binding sites. At nanomolar concentrations, DS activated the channel by causing three-to fivefold increases in open-state probability and dwell times. At micromolar concentrations, DS first increased then reduced activity in the channels; with the dominant effect being reduced activity. A 20 nm concentration of DS produced significant contracture tension in human muscle from one MH subject and caused potentiation of twitch in muscle from another MH patient. Halothane contracture in MH dog muscle was followed by an additional increase in tension when treated with 20 nm DS. Other investigations on chemically skinned, human fibers showed that calcium loaded in the sarcoplasmic reticulum was partially released by nM DS. CONCLUSIONS: The study results suggest that at least two binding sites for DS exist on the Ry1 receptor calcium channel. A low-affinity (microM) site is associated with reduced channel gating and open-state dwell time and may relate to the established pharmacologic muscle relaxant effect of DS. The proposed high-affinity (nM) DS binding site activates the channel, producing Ca2+ release to the myoplasm, which, under environmentally adverse conditions, could damage genetically predisposed MH muscle. Such a phenomenon, if it occurs in DS treated MH patients, could generate a recrudescence of the syndrome.
Asunto(s)
Canales de Calcio/efectos de los fármacos , Dantroleno/farmacología , Proteínas Musculares/efectos de los fármacos , Relajantes Musculares Centrales/farmacología , Músculo Esquelético/efectos de los fármacos , Animales , Perros , Humanos , Técnicas In Vitro , Hipertermia Maligna/etiología , Músculo Esquelético/metabolismo , Canal Liberador de Calcio Receptor de Rianodina , PorcinosRESUMEN
1. The pharmacokinetics of different pharmaceutical preparations of oral nifedipine--Adalat (capsule), Oxcord and Cardalin (tablets)--was determined after administration of single oral doses of 10 mg to nine healthy young Brazilian volunteers (7 men). 2. There were no significant changes in heart rate or systolic and diastolic blood pressure measured in the sitting position within 8 h of nifedipine administration to these normotensive volunteers. No side effects were reported by the volunteers or observed by the attending physicians during the study. 3. No significant differences were observed among the three preparations in relation to the following pharmacokinetic parameters obtained from the plasma concentration-time curves: area under the curve (AUC), slope (beta) and half-life (T1/2) of the elimination phase, volume of distribution (Vd/F) and total body clearance (CL/F), both expressed as functions of the oral bioavailability (F) of nifedipine. 4. The peak plasma concentration of nifedipine (Cmax) and the time to reach Cmax (Tmax) were not different for the two tablet preparations. However, Cmax was significantly higher, and Tmax was significantly shorter for the capsule. These data indicate that the capsule and the tablet preparations are not bioequivalent.
Asunto(s)
Nifedipino/farmacocinética , Administración Oral , Adulto , Presión Sanguínea/efectos de los fármacos , Brasil , Formas de Dosificación , Femenino , Frecuencia Cardíaca/efectos de los fármacos , Humanos , Masculino , Nifedipino/farmacologíaRESUMEN
The pharmacokinetics of different pharmaceutical preparations of oral nifedipine-Adalat (capsule), Oxcord and Cardalin (tablets)-was determined after administration of single oral doses of 10 mg to nine healthy young Brazilian volunteers (7 men). There no significant changes in heart rate or systolic and diastolic blood pressure measured in the sitting position within 8 h of nifedipine administration to these normotensive volunteers. No side effects were reported by the volunteers or observed by the attending physicians during the study. No significant differences were observed among the three preparations in relation to the following pharmacokinetic parameters obtained from the plasma concentration-time curves: area under the curve (AUC), slope (beta) and half-life (T½) of the elimination phase, volume of distribution (Vd/F) and total body clearance (CL/F), both expre4ssed as functions of the oral bioavailability (F) of nifedipine. The peak, plasma concentration of nifedipine (C max) and the time to reach C max (T max) were not different for the rwo tablet preparations. However, C max was significantly higher, and T max was significantly shorter for the capsule. These data indicate that the capsule and the tablet preparations are not bioequivalent
Asunto(s)
Disponibilidad Biológica , Bloqueadores de los Canales de Calcio , Nifedipino/farmacocinética , Farmacocinética , Nifedipino/administración & dosificaciónRESUMEN
To examine if chronic sodium loading on the brain produces sustained increases in blood pressure, water intake, and sodium excretion, hypertonic (0.5 M and 1.5 M) and isotonic (0.15 M) NaCl solutions were infused into the third ventricle of Sprague-Dawley rats at a rate of 5.5 microliters/hr for 7 days. Intracerebroventricular infusion of 1.5 M NaCl significantly increased systolic blood pressure during the entire infusion period (+23 +/- 5 mm Hg on day 1 and +15 +/- 2 mm Hg on day 7, n = 10, mean +/- SEM). Blood pressure rose insignificantly in the 0.5 M NaCl group, whereas it remained at the baseline levels in the 0.15 M NaCl group. The increases in water intake (day 2), positive water balance (day 2), and negative sodium balance (day 3) were observed in the 1.5 M NaCl group. On day 7, the 1.5 M NaCl group showed hyponatremia and low plasma osmolality and had higher plasma norepinephrine but not vasopressin compared with the 0.15 M NaCl group. In another series of study, depressor response to intravenous hexamethonium (20 mg/kg) in the 1.5 M NaCl group was greater than that in the 0.15 M NaCl group on both day 1 and 7. The depressor response to d(CH2)5Tyr(Me)-arginine vasopressin (10 micrograms/kg) in the 1.5 M NaCl group was greater on day 1 but not on day 7. These results indicate that sustained sodium stimulus on the central nervous system causes mild hypertension and alters water and sodium balance. The sympathetic nervous system but not vasopressin may play an important role in the chronic phase of central NaCl-induced hypertension.
Asunto(s)
Presión Sanguínea/efectos de los fármacos , Cloruro de Sodio/farmacología , Equilibrio Hidroelectrolítico/efectos de los fármacos , Animales , Cateterismo , Ventrículos Cerebrales , Ingestión de Líquidos/efectos de los fármacos , Frecuencia Cardíaca/efectos de los fármacos , Masculino , Ratas , Ratas Endogámicas , Sodio/líquido cefalorraquídeo , Vasopresinas/fisiologíaRESUMEN
The effects of halothane or cooling on Ca2(+)-activated tensions and on the uptake and release of Ca2+ by the sarcoplasmic reticulum were investigated in chemically skinned fibers of the extensor digitorum longus muscle of adult rabbits. At 22 degrees C, halothane (greater than 0.46 mM) induced Ca2+ release from the SR of Ca2(+)-loaded skinned fibers that resulted in transient tensions. Higher concentrations of halothane (greater than 4.65 mM) reduced the steady-state accumulation of Ca2+ in the SR at 22 degrees C. Cooling (to less than 10 degrees C) elicited transient contractures (cooling-induced contractures [CC]) in Ca2(+)-loaded skinned fibers, despite the fact that the tensions elicited by adding Ca2+ to the bath were depressed at these low temperatures. The skinned fibers did not develop CCs at 12-16 degrees C. Halothane cooling contractures could be elicited at these temperatures by exposing the fibers to halothane concentrations that failed to elicit Ca2+ release at 22 degrees C. The halothane cooling contractures were blocked by procaine but not by lidocaine. It was concluded that these contractures resulted from a synergistic interaction between halothane and cooling that stimulates Ca2+ release from, and reduces Ca2+ uptake by, the sarcoplasmic reticulum.